Philip Ferneau, MBA, JD

Phil co-founded Borealis Ventures in 2002 and has led the firm’s healthcare investing from its inception.   He currently leads Borealis’ investments in Adimab, Amagma, Avitide, Compass Therapeutics, Evox Therapeutics, Orbit Discovery, Ovation.io, Teckro, and T-Cypher Bio.  Phil’s prior investments include Avedro (IPO, then acquired by Glaukos), GlycoFi (acquired by Merck & Co.), M2S (acquired by AIG Altaris Health Partners), and Vets First Choice (Nasdaq: CVET).

Phil has also spent over 20 years advancing innovation ecosystems at Dartmouth College and other universities.  He is an adjunct professor at Dartmouth’s Tuck School of Business, teaching venture capital topics. Phil began his career in private legal practice, counseling technology startups, Fortune 500 companies, and foreign governments on sensitive trade, tax, and investment matters.

Phil received an A.B. degree from Dartmouth College, a J.D. from the University of Virginia School of Law, and a M.B.A. (Edward Tuck Scholar with High Distinction) from the Tuck School of Business at Dartmouth.